「低分子」の写真・グラフィックス・映像

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2017年09月13日

  中国の研究チーム、神経膠腫治療に新たな道筋示す

  実験を行う研究チームのメンバー。（２０１７年９月１３日撮影）中国科学院合肥腫瘤医院医学病理部の方志友（ほう・しゆう）研究員と陳学冉（ちん・がくぜん）副研究員のチームがこのほど、スクリーニングにより、悪性神経膠腫（グリオーマ）治療の鍵となる低分子薬剤を発見した。研究成果は学術誌「Ｔｈｅｒａｎｏｓｔｉｃｓ」に巻頭記事として掲載された。（合肥＝新華社配信）＝２０１７（平成２９）年９月１３日、クレジット：新華社／共同通信イメージズ

  商品コード: 2020012321047

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2017年09月13日

  中国の研究チーム、神経膠腫治療に新たな道筋示す

  実験を行う研究チームのメンバー。（２０１７年９月１３日撮影）中国科学院合肥腫瘤医院医学病理部の方志友（ほう・しゆう）研究員と陳学冉（ちん・がくぜん）副研究員のチームがこのほど、スクリーニングにより、悪性神経膠腫（グリオーマ）治療の鍵となる低分子薬剤を発見した。研究成果は学術誌「Ｔｈｅｒａｎｏｓｔｉｃｓ」に巻頭記事として掲載された。（合肥＝新華社配信）＝２０１７（平成２９）年９月１３日、クレジット：新華社／共同通信イメージズ

  商品コード: 2020012321052

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2020年01月14日

  中国の研究チーム、神経膠腫治療に新たな道筋示す

  今回の研究の概略図。遺伝子ＺＤＨＨＣ１７と分裂促進因子活性化タンパク質キナーゼキナーゼ４（ＭＡＰ２Ｋ４）の複合体は、Ｃ－ＪｕｎＮ末端キナーゼ（ＪＮＫｓ）とｐ３８のシグナル伝達を活性化させ、神経膠腫の悪性化を招く。ゲニステイン薬剤はこの複合体の結合を防ぎ、腫瘍の成長を阻害する。（資料写真）中国科学院合肥腫瘤医院医学病理部の方志友（ほう・しゆう）研究員と陳学冉（ちん・がくぜん）副研究員のチームがこのほど、スクリーニングにより、悪性神経膠腫（グリオーマ）治療の鍵となる低分子薬剤を発見した。研究成果は学術誌「Ｔｈｅｒａｎｏｓｔｉｃｓ」に巻頭記事として掲載された。（合肥＝新華社配信）＝撮影日不明、クレジット：新華社／共同通信イメージズ

  商品コード: 2020012320995

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2020年01月14日

  中国の研究チーム、神経膠腫治療に新たな道筋示す

  今回の研究の概略図。遺伝子ＺＤＨＨＣ１７と分裂促進因子活性化タンパク質キナーゼキナーゼ４（ＭＡＰ２Ｋ４）の複合体は、Ｃ－ＪｕｎＮ末端キナーゼ（ＪＮＫｓ）とｐ３８のシグナル伝達を活性化させ、神経膠腫の悪性化を招く。ゲニステイン薬剤はこの複合体の結合を防ぎ、腫瘍の成長を阻害する。（資料写真）中国科学院合肥腫瘤医院医学病理部の方志友（ほう・しゆう）研究員と陳学冉（ちん・がくぜん）副研究員のチームがこのほど、スクリーニングにより、悪性神経膠腫（グリオーマ）治療の鍵となる低分子薬剤を発見した。研究成果は学術誌「Ｔｈｅｒａｎｏｓｔｉｃｓ」に巻頭記事として掲載された。（合肥＝新華社配信）＝撮影日不明、クレジット：新華社／共同通信イメージズ

  商品コード: 2020012321040

• 本映像はログイン後にご覧いただけます

  00:53.01

  検討リストへ

  2020年01月14日

  「新華社」中国の研究チーム、神経膠腫治療に新たな道筋示す

  中国科学院合肥腫瘤医院医学病理部の方志友（ほう・しゆう）研究員と陳学冉（ちん・がくぜん）副研究員のチームはこのほど、スクリーニングにより、悪性神経膠腫（グリオーマ）治療の鍵となる低分子薬剤を発見した。研究成果は学術誌「Ｔｈｅｒａｎｏｓｔｉｃｓ」に巻頭記事として掲載された。陳氏は、脳腫瘍の一種である神経膠腫は発症率が中国で上位５番以内になっていると指摘。ヒトの脳の血液脳関門には保護障壁があり、これまで多くの治療薬がこの障壁を通過できず、そのため腫瘍部位の治療ができなかったと説明した。今回のスクリーニングで得られたゲニステイン薬剤は、この障壁を突破できるとされ、研究の結果、この薬剤は遺伝子ＺＤＨＨＣ１７と分裂促進因子活性化タンパク質キナーゼキナーゼ４（ＭＡＰ２Ｋ４）の結合や、Ｃ－ＪｕｎＮ末端キナーゼ（ＪＮＫｓ）とｐ３８のシグナル伝達を効果的に阻害するだけでなく、神経膠細胞（グリア細胞）の増殖や浸潤など悪性の働きの拡大も大幅に阻害できることがわかった。研究では神経膠腫発生の根本原因を明らかにしただけでなく、神経膠腫の治療とがん再発防止のための新たな考えを提供した。（記者／水金辰、屈彦）＜映像内容＞神経膠腫治療の鍵となる低分子薬剤を発見、研究の様子、撮影日：撮影日不明、クレジット：新華社／共同通信イメージズ

  商品コード: 2020012322893

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2020年11月14日

  COVID-19 Vaccines: BioNTech

  BioNTech、クレジット：／共同通信イメージズ

  商品コード: 2020111602122

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2022年09月22日

  Europa Press and Idorsia briefing on sleep as a pillar of social welfare

  September 22, 2022, Madrid, Spain: The researcher and coordinator of the Occupational Risk Prevention Service at Hospital de Castellón, Carmen Bellido Cambrón, speaks during an informative meeting of Idorsia and Europa Press, under the title ‘Sleep, a pillar of social welfare: scientific talent in the field of sleep‘, at the Meeting Place Hotel, on September 22, 2022, in Madrid (Spain). The Swiss-based biopharmaceutical company Idorsia specializes in the development and commercialization of small molecule treatments. Last May, Idorsia reached a milestone in its history when the European Commission granted marketing authorization for the first drug in its portfolio, indicated for the treatment of chronic insomnia in adults. According to the Spanish Society of Neurology, between 20 and 48% of the Spanish adult population suffers from difficulty in initiating or maintaining sleep...22 SEPTEMBER 2022;MEDICINE;NEUROLOGY;SLEEP;INSOMNIA;DRUG;PHARMACEUTICAL..Marta Fernández Jara / Europa Press..09/22/2022 (C...

  商品コード: 2022092506182

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2022年09月22日

  Europa Press and Idorsia briefing on sleep as a pillar of social welfare

  September 22, 2022, Madrid, Spain: Idorsia‘s executive vice president, Martine Clozel; speaks at the Idorsia and Europa Press briefing entitled ‘Sleep, a pillar of social well-being: scientific talent in the field of sleep‘, at the Meeting Place Hotel, September 22, 2022, in Madrid (Spain). The Swiss-based biopharmaceutical company Idorsia specializes in the development and commercialization of small molecule treatments. Last May, Idorsia reached a milestone in its history when the European Commission granted marketing authorization for the first drug in its portfolio, indicated for the treatment of chronic insomnia in adults. According to the Spanish Society of Neurology, between 20 and 48% of the Spanish adult population suffers from difficulty in initiating or maintaining sleep...22 SEPTEMBER 2022;MEDICINE;NEUROLOGY;SLEEP;INSOMNIA;DRUG;PHARMACEUTICAL..Marta Fernández Jara / Europa Press..09/22/2022 (Credit Image: © Marta FernáNdez Jara/Contacto via ZUMA Press)、クレジット：©Ｍａｒｔａ　ＦｅｒｎáＮｄｅｚ　Ｊａｒａ／Ｃｏｎｔａｃｔ...

  商品コード: 2022092506909

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2022年09月22日

  Europa Press and Idorsia briefing on sleep as a pillar of social welfare

  September 22, 2022, Madrid, Spain: (L-R) The president of the Spanish Federation of Sleep Medicine Societies, Carlos Javier Egea Santaolalla; the researcher and coordinator of the Occupational Risk Prevention Service at Castellón Hospital, Carmen Bellido Cambrón; and the professor and Ramón y Cajal researcher in Neurodegenerative Diseases, CIBERNED, IBIMA, and University of Málaga, Inés Moreno; during an informative meeting of Idorsia and Europa Press, under the title ‘Sleep, a pillar of social welfare: Scientific talent in the field of sleep‘, at the Meeting Place Hotel, on September 22, 2022, in Madrid (Spain). The Swiss-based biopharmaceutical company Idorsia specializes in the development and commercialization of small molecule treatments. Last May, Idorsia reached a milestone in its history when the European Commission granted marketing authorization for the first drug in its portfolio, indicated for the treatment of chronic insomnia in adults. According to the Spanish Society of Neurology, ...

  商品コード: 2022092506141

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2022年09月22日

  Europa Press and Idorsia briefing on sleep as a pillar of social welfare

  September 22, 2022, Madrid, Spain: The president of the Spanish Federation of Sleep Medicine Societies, Carlos Javier Egea Santaolalla, speaks during an informative meeting of Idorsia and Europa Press, under the title ‘Sleep, a pillar of social welfare: scientific talent in the field of sleep‘, at the Meeting Place Hotel, on September 22, 2022, in Madrid (Spain). The Swiss-based biopharmaceutical company Idorsia specializes in the development and commercialization of small molecule treatments. Last May, Idorsia reached a milestone in its history when the European Commission granted marketing authorization for the first drug in its portfolio, indicated for the treatment of chronic insomnia in adults. According to the Spanish Society of Neurology, between 20 and 48% of the Spanish adult population suffers from difficulty in initiating or maintaining sleep...SEPTEMBER 22;2022..Marta Fernández Jara / Europa Press..09/22/2022 (Credit Image: © Marta FernáNdez Jara/Contacto via ZUMA Press)、クレジット：©Ｍａｒｔａ　Ｆｅｒｎ...

  商品コード: 2022092505875

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2022年09月22日

  Europa Press and Idorsia briefing on sleep as a pillar of social welfare

  September 22, 2022, Madrid, Spain: The president of the Spanish Federation of Sleep Medicine Societies, Carlos Javier Egea Santaolalla, speaks during an informative meeting of Idorsia and Europa Press, under the title ‘Sleep, a pillar of social welfare: scientific talent in the field of sleep‘, at the Meeting Place Hotel, on September 22, 2022, in Madrid (Spain). The Swiss-based biopharmaceutical company Idorsia specializes in the development and commercialization of small molecule treatments. Last May, Idorsia reached a milestone in its history when the European Commission granted marketing authorization for the first drug in its portfolio, indicated for the treatment of chronic insomnia in adults. According to the Spanish Society of Neurology, between 20 and 48% of the Spanish adult population suffers from difficulty in initiating or maintaining sleep...SEPTEMBER 22;2022..Marta Fernández Jara / Europa Press..09/22/2022 (Credit Image: © Marta FernáNdez Jara/Contacto via ZUMA Press)、クレジット：©Ｍａｒｔａ　Ｆｅｒｎ...

  商品コード: 2022092506095

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2022年09月22日

  Europa Press and Idorsia briefing on sleep as a pillar of social welfare

  September 22, 2022, Madrid, Spain: (L-R) The president of the Spanish Federation of Sleep Medicine Societies, Carlos Javier Egea Santaolalla; the researcher and coordinator of the Occupational Risk Prevention Service at Castellón Hospital, Carmen Bellido Cambrón; the professor and researcher Ramón y Cajal in Neurodegenerative Diseases, CIBERNED, IBIMA, and University of Malaga, Inés Moreno; and the head of the Neurology Service of the La Mancha Centro Hospital Complex, Ana María González Manero; during an informative meeting organized by Idorsia and Europa Press, under the title ‘Sleep, a pillar of social welfare: Scientific talent in the field of sleep‘, at the Meeting Place Hotel, on September 22, 2022, in Madrid (Spain). The Swiss-based biopharmaceutical company Idorsia specializes in the development and commercialization of small molecule treatments. Last May, Idorsia reached a milestone in its history when the European Commission granted marketing authorization for the first drug in its po...

  商品コード: 2022092506109

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2022年09月22日

  Europa Press and Idorsia briefing on sleep as a pillar of social welfare

  September 22, 2022, Madrid, Spain: Journalist and consultant Emilio de Benito closes the informative meeting of Idorsia and Europa Press, under the title ‘Sleep, a pillar of social welfare: scientific talent in the field of sleep‘, at the Meeting Place Hotel, on September 22, 2022, in Madrid (Spain). The Swiss-based biopharmaceutical company Idorsia specializes in the development and commercialization of small molecule treatments. Last May, Idorsia reached a milestone in its history when the European Commission granted marketing authorization for the first drug in its portfolio, indicated for the treatment of chronic insomnia in adults. According to the Spanish Society of Neurology, between 20 and 48% of the Spanish adult population suffers from difficulty in initiating or maintaining sleep...22 SEPTEMBER 2022;MEDICINE;NEUROLOGY;SLEEP;INSOMNIA;DRUG;PHARMACEUTICAL..Marta Fernández Jara / Europa Press..09/22/2022 (Credit Image: © Marta FernáNdez Jara/Contacto via ZUMA Press)、クレジット：©Ｍａｒｔａ　ＦｅｒｎáＮｄｅｚ　Ｊａ...

  商品コード: 2022092506632

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2022年09月22日

  Europa Press and Idorsia briefing on sleep as a pillar of social welfare

  September 22, 2022, Madrid, Spain: Journalist and consultant Emilio de Benito closes the informative meeting of Idorsia and Europa Press, under the title ‘Sleep, a pillar of social welfare: scientific talent in the field of sleep‘, at the Meeting Place Hotel, on September 22, 2022, in Madrid (Spain). The Swiss-based biopharmaceutical company Idorsia specializes in the development and commercialization of small molecule treatments. Last May, Idorsia reached a milestone in its history when the European Commission granted marketing authorization for the first drug in its portfolio, indicated for the treatment of chronic insomnia in adults. According to the Spanish Society of Neurology, between 20 and 48% of the Spanish adult population suffers from difficulty in initiating or maintaining sleep...22 SEPTEMBER 2022;MEDICINE;NEUROLOGY;SLEEP;INSOMNIA;DRUG;PHARMACEUTICAL..Marta Fernández Jara / Europa Press..09/22/2022 (Credit Image: © Marta FernáNdez Jara/Contacto via ZUMA Press)、クレジット：©Ｍａｒｔａ　ＦｅｒｎáＮｄｅｚ　Ｊａ...

  商品コード: 2022092506917

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2022年09月22日

  Europa Press and Idorsia briefing on sleep as a pillar of social welfare

  September 22, 2022, Madrid, Spain: The journalist Emilio de Benito; the executive vice-president of Idorsia, Martine Clozel; the head of the Neurology Service of the La Mancha Centro Hospital Complex, Ana María González Manero; the professor and researcher Ramón y Cajal in Neurodegenerative Diseases, CIBERNED, IBIMA, and University of Malaga, Inés Moreno; the researcher and coordinator of the Occupational Risk Prevention Service at the Hospital de Castellón, Carmen Bellido Cambrón; and the president of the Spanish Federation of Sleep Medicine Societies, Carlos Javier Egea Santaolalla; pose after the informative meeting organized by Idorsia and Europa Press, under the title ‘Sleep, a pillar of social welfare: Scientific talent in the field of sleep‘, at the Meeting Place Hotel, on September 22, 2022, in Madrid (Spain). The Swiss-based biopharmaceutical company Idorsia specializes in the development and commercialization of small molecule treatments. Last May, Idorsia reached a milestone in its h...

  商品コード: 2022092506937

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2022年09月22日

  Europa Press and Idorsia briefing on sleep as a pillar of social welfare

  September 22, 2022, Madrid, Spain: The researcher and coordinator of the Occupational Risk Prevention Service at Hospital de Castellón, Carmen Bellido Cambrón, speaks during an informative meeting of Idorsia and Europa Press, under the title ‘Sleep, a pillar of social welfare: scientific talent in the field of sleep‘, at the Meeting Place Hotel, on September 22, 2022, in Madrid (Spain). The Swiss-based biopharmaceutical company Idorsia specializes in the development and commercialization of small molecule treatments. Last May, Idorsia reached a milestone in its history when the European Commission granted marketing authorization for the first drug in its portfolio, indicated for the treatment of chronic insomnia in adults. According to the Spanish Society of Neurology, between 20 and 48% of the Spanish adult population suffers from difficulty in initiating or maintaining sleep...22 SEPTEMBER 2022;MEDICINE;NEUROLOGY;SLEEP;INSOMNIA;DRUG;PHARMACEUTICAL..Marta Fernández Jara / Europa Press..09/22/2022 (C...

  商品コード: 2022092505787

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2022年09月22日

  Europa Press and Idorsia briefing on sleep as a pillar of social welfare

  September 22, 2022, Madrid, Spain: (L-R) The president of the Spanish Federation of Sleep Medicine Societies, Carlos Javier Egea Santaolalla; the researcher and coordinator of the Occupational Risk Prevention Service at Castellón Hospital, Carmen Bellido Cambrón; the professor and researcher Ramón y Cajal in Neurodegenerative Diseases, CIBERNED, IBIMA, and University of Malaga, Inés Moreno; and the head of the Neurology Service of the La Mancha Centro Hospital Complex, Ana María González Manero; during an informative meeting organized by Idorsia and Europa Press, under the title ‘Sleep, a pillar of social welfare: Scientific talent in the field of sleep‘, at the Meeting Place Hotel, on September 22, 2022, in Madrid (Spain). The Swiss-based biopharmaceutical company Idorsia specializes in the development and commercialization of small molecule treatments. Last May, Idorsia reached a milestone in its history when the European Commission granted marketing authorization for the first drug in its po...

  商品コード: 2022092506248

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2023年01月09日

  CHINA-SHANGHAI-COMMUNITY HEALTH CENTERS-COVID-19 DRUGS (CN)

  (230109) -- SHANGHAI, Jan. 9, 2023 (Xinhua) -- A pharmacist checks a prescription at a community health service center in Minhang District in east China‘s Shanghai, Jan. 8, 2023. Small-molecule COVID-19 drugs have been put into use in community health service centers in Shanghai. (Xinhua/Wang Xiang)＝ 配信日： ２０２３（令和５）年１月９日、クレジット：新華社／共同通信イメージズ

  商品コード: 2023010910054

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2023年01月09日

  CHINA-SHANGHAI-COMMUNITY HEALTH CENTERS-COVID-19 DRUGS (CN)

  (230109) -- SHANGHAI, Jan. 9, 2023 (Xinhua) -- A doctor prescribes small-molecule COVID-19 drugs for a patient at a community health service center in Minhang District in east China‘s Shanghai, Jan. 8, 2023. Small-molecule COVID-19 drugs have been put into use in community health service centers in Shanghai. (Xinhua/Wang Xiang)＝ 配信日： ２０２３（令和５）年１月９日、クレジット：新華社／共同通信イメージズ

  商品コード: 2023010910074

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2023年01月09日

  CHINA-SHANGHAI-COMMUNITY HEALTH CENTERS-COVID-19 DRUGS (CN)

  (230109) -- SHANGHAI, Jan. 9, 2023 (Xinhua) -- Wang Liyun (R), head of medical department, and a staff member from nursing facility, checks distribution list for small-molecule COVID-19 drugs at a community health service center in Minhang District in east China‘s Shanghai, Jan. 8, 2023. Small-molecule COVID-19 drugs have been put into use in community health service centers in Shanghai. (Xinhua/Wang Xiang)＝ 配信日： ２０２３（令和５）年１月９日、クレジット：新華社／共同通信イメージズ

  商品コード: 2023010910072

• 本画像はログイン後にご覧いただけます

  検討リストへ

  2023年01月09日

  CHINA-SHANGHAI-COMMUNITY HEALTH CENTERS-COVID-19 DRUGS (CN)

  (230109) -- SHANGHAI, Jan. 9, 2023 (Xinhua) -- A patient registers at a community health service center in Minhang District in east China‘s Shanghai, Jan. 8, 2023. Small-molecule COVID-19 drugs have been put into use in community health service centers in Shanghai. (Xinhua/Wang Xiang)＝ 配信日： ２０２３（令和５）年１月９日、クレジット：新華社／共同通信イメージズ

  商品コード: 2023010910065